

Help ensure post-discharge compliance.




You can enroll patients prescribed LOVENOX[®] in a free Patient Reminder service.

This service provides prescription reminders and helpful resources about therapy with LOVENOX[®]. All you need to do is register the patient and the service contacts them within 24 hours of discharge.

LOVENOX[®] patients have access to free:

- Patient Reminder Service 24-hours post-discharge
- Patient Hotline with live support via telephone

To enroll your patients in our Patient Reminder service, use the fax-back form on the reverse side.



Encourage your patients to call our Patient Hotline for help with self-administering LOVENOX[®] at home.

Patients who have been determined to be at risk for DVT may be encouraged to continue treatment at home. To assist these patients, we've created the At Home With LOVENOX[®] Discharge Kit featuring a step-by-step guide to self-injections.

- Encourage appropriate patients to use the **Patient Hotline (1-800-633-1610, Option 1)** which puts them in touch with a healthcare professional who can answer any additional questions
- There is no charge for this service. It is free to LOVENOX[®] patients
- The hotline is a simple and effective way to provide support when patients are no longer under your care

Developed and provided by sanofi-aventis.

Please see the important safety information on back.

Please see the attached full prescribing information, including boxed WARNING.

LOVENOX® (enoxaparin sodium injection) Patient Reminder Service Enrollment Form

Dear Health Care Professional: To support at-home compliance with LOVENOX® therapy, please fill in this form on behalf of your patients and fax to 800-933-3243. The patient will be contacted at home within 24 hours of discharge.

Patient Name _____ Discharge Date ____/____/____

Phone number _____

Home Address _____

Name of hospital _____

Nurse/staff name and title _____

LOVENOX® is indicated for the prophylaxis of deep vein thrombosis which may lead to pulmonary embolism

- In medical patients who are at risk for thromboembolic complications due to severely restricted mobility during acute illness
- In patients undergoing hip-replacement surgery, during and following hospitalization
- In patients undergoing knee-replacement surgery

Privacy Statement

sanofi-aventis U.S.LLC respects your interest in keeping your personal health information private. We will not sell or rent your information to any third parties or outside mailing lists. For more information, see our Privacy Policy <http://www.privacypolicy.sanofi-aventis.us/>

By signing below I agree that the information I provide may be used by sanofi-aventis U.S.LLC, its affiliates, and the business service companies working with the company to:

- Provide me with information about DVT-related conditions and products that treat this condition; and
- Develop products and services concerning DVT, which may include market research.

Signature of patient _____ Date ____/____/____

Signature of Health Care Professional _____ Date ____/____/____

Important Safety Information

Certain procedures, called “epidural/spinal anesthesia” and “spinal puncture,” may be used as a normal part of hospitalization. Patients requiring these procedures while being treated with LOVENOX® (enoxaparin sodium injection) or other low-molecular-weight heparins are at risk of developing a blood clot in or around the spine. This condition may result in long-term or permanent paralysis.

LOVENOX® is not the same as “unfractionated heparin” or other drugs called “low-molecular-weight heparins.” Therefore, these drugs cannot be used interchangeably with LOVENOX®.

LOVENOX® can alter the blood's ability to clot. Patients treated with LOVENOX®, who also have conditions affecting the clotting system, must be carefully monitored by their physician. Adjusting the dose of LOVENOX® may be necessary for patients who have certain forms of kidney disease. All patients receiving LOVENOX®, as well as other anticoagulants, should be carefully monitored for bleeding by their physician. Bleeding can occur at any site with LOVENOX® use.

Platelet drops, known as “thrombocytopenia,” can occur with LOVENOX® use. Cases of a related condition called “heparin-induced thrombocytopenia” have been observed in clinical practice. If you have had this condition, you must notify your healthcare professional. Your physician may perform blood tests to monitor for the occurrence of any drop in platelet count.

The use of LOVENOX® has not been adequately studied in pregnant women with artificial (mechanical) heart valves.

LOVENOX® should not be used in patients with an allergy or sensitivity reaction to the active ingredient called enoxaparin sodium, heparin, or pork products, and in patients with active major bleeding.

Common side effects include mild local reactions or irritation at the site of injection, pain, bruising, and redness of skin.

For specific questions about your health, you should always consult your physician or a qualified healthcare professional who is responsible for your care.

Please see accompanying full prescribing information, including boxed WARNING.

